Wolfe Lifts Eli Lilly Price Target Citing Bigger Market for Oral Obesity Pill
Wolfe Research raised its price target on Eli Lilly to $1,325 from $1,250 and maintained an Outperform rating after increasing long-term sales projections for the company’s investigational oral obesity therapy, orforglipron. The firm now expects peak annual revenue for the pill to reach about $44 billion, up from a prior $32 billion forecast and ab…